铁蛋白升高经IL-18介导与ARDS全身炎症及死亡率相关
在HARP-2(英国,511例)和ROSE(美国,847例)两项RCT的ARDS患者中,基线血浆铁蛋白与28天死亡率相关,铁蛋白每增加一个对数倍数OR为1.71(95%CI 1.01–2.90)。铁蛋白>1380 ng/mL者28天死亡率更高、无呼吸机天数更少;中介分析显示IL-18是铁蛋白与死亡率之间的中间通路。
要点
- ARDS患者基线铁蛋白升高与28天死亡率独立相关。
- 铁蛋白>1380 ng/mL者死亡率更高且无呼吸机天数更少。
- IL-18介导铁蛋白与死亡率之间的关联,提示免疫调节靶点。
核心结论
- 铁蛋白是ARDS临床有用的生物标志物,与更差的患者结局相关。
- 结果为针对高铁蛋白ARDS亚组、靶向IL-18的免疫调节剂前瞻性干预试验提供支持。
研究设计与样本
- 基于两项随机对照试验的队列分析:HARP-2(发现队列,英国,辛伐他汀试验)和ROSE(验证队列,美国,神经肌肉阻滞试验)。
- HARP-2测铁蛋白511例(占入组95%),ROSE测铁蛋白847例(占入组84%)。
- 采用限制性立方样条逻辑回归模型确定与28天死亡率相关的铁蛋白阈值。
主要发现
- 铁蛋白在两项研究中均与28天死亡率一致相关。
- 荟萃分析显示,铁蛋白每增加一个对数倍数,28天死亡率OR为1.71(95%CI 1.01–2.90)。
- 铁蛋白>1380 ng/mL者(HARP-2占28%,ROSE占24%)在两项研究中28天死亡率显著更高、无呼吸机天数更少。
- 中介分析(纳入APACHE-II评分和ARDS病因等混杂因素)显示IL-18作为铁蛋白与死亡率之间的中间通路具有统计学显著贡献。
关键数值与推荐
- 铁蛋白阈值:>1380 ng/mL(HARP-2中占28%,ROSE中占24%)。
- 铁蛋白每增加一个对数倍数与28天死亡率OR 1.71(95%CI 1.01–2.90)相关。
临床怎么用
- 可将基线血浆铁蛋白用于ARDS风险分层,识别高死亡率亚组。
- 铁蛋白>1380 ng/mL提示高炎症亚型,可考虑IL-18靶向免疫调节的临床试验场景。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Inflammatory subphenotypes have been identified in acute respiratory distress syndrome (ARDS). Hyperferritinaemia in sepsis is associated with hyperinflammation, worse clinical outcomes, and may predict benefit with immunomodulation. Our aim was to determine if raised ferritin identified a subphenotype in patients with ARDS. METHODS: Baseline plasma ferritin concentrations were measured in patients with ARDS from two randomised controlled trials of simvastatin (Hydroxymethylglutaryl-CoA Reductase Inhibition with Simvastatin in Acute Lung Injury to Reduce Pulmonary Dysfunction-2 (HARP-2); discovery cohort, UK) and neuromuscular blockade (ROSE; validation cohort, USA). Results were analysed using a logistic regression model with restricted cubic splines, to determine the ferritin threshold associated with 28-day mortality. RESULTS: Ferritin was measured in 511 patients from HARP-2 (95% of patients enrolled) and 847 patients (84% of patients enrolled) from ROSE. Ferritin was consistently associated with 28-day mortality in both studies and following a meta-analysis, a log-fold increase in ferritin was associated with an OR 1.71 (95% CI 1.01 to 2.90) for 28-day mortality. Patients with ferritin >1380 ng/mL (HARP-2 28%, ROSE 24%) had a significantly higher 28-day mortality and fewer ventilator-free days in both studies. Mediation analysis, including confounders (acute physiology and chronic health evaluation-II score and ARDS aetiology) demonstrated a statistically significant contribution of interleukin (IL)-18 as an intermediate pathway between ferritin and mortality. CONCLUSIONS: Ferritin is a clinically useful biomarker in ARDS and is associated with worse patient outcomes. These results provide support for prospective interventional trials of immunomodulatory agents targeting IL-18 in this hyperferritinaemic subgroup of patients with ARDS.
引用
- Mehta P, Samanta RJ, Wick K, et al. Elevated ferritin, mediated by IL-18 is associated with systemic inflammation and mortality in acute respiratory distress syndrome (ARDS). Thorax. 2024. PMID: 38148147. doi:10.1136/thorax-2023-220292
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。